Karnataka Pharma accelerates its Worldwide Footprint with a Centre of Excellence to Boost Innovation

Karnataka Pharma is stepping up its efforts to strengthen its worldwide reach by establishing a Centre of Excellence to boost innovation. Because of its emphasis on unique medications, new drug delivery methods, and regulatory compliance, the state is known around the world as a destination for high-quality products. In terms of total production units, Karnataka accounts for around 2% of total production units, accounting for 7% of overall turnover. While India has the most US FDA factories, this state has a considerable number of them, according to Harish K Jain, president of the Karnataka Drugs and Pharmaceutical Manufacturers Association (KDPMA) and director of Embiotic Labs.

Pharma companies in this region export to over 100 nations. In fact, Karnataka produces seven of the top twenty brands in the country. One intriguing figure is that we have one of the lowest percentages of substandard quality pharmaceuticals in the country, with our state reporting only 0.8% compared to the national average of roughly 2%. Following the Union government's support through the productivity linked incentive (PLI) and the Promotion of Research and Innovation in Pharma and Med-Tech Sector (PRIP) schemes, companies in Karnataka will work to reap the benefits of these initiatives in the coming years. The state pharma sector implemented new Schedule M without asking for an extension. The regular workshops for the sector have inculcated the much-needed accountability to remain compliant to the highest standards of quality. Also from Schedule M, companies are moving up to be PICs complaint.

Karnataka has long been a centre of innovation and best worldwide practises. Companies in this region pioneered high-end contract manufacturing for the production of biologics, vaccines, and bulk pharmaceuticals that are well-known in global markets. Our focus is now on increasing the volume and value of our capacity across bulk pharmaceuticals, formulations, biologics, biosimilars, drug development, and medical devices. Because of its scientific prowess, Karnataka will undoubtedly lead from the front for the next generation of innovation and research that will occur in India, he said. The Centre of Excellence is envisaged to provide common early stage development with training facilities, and auditorium to host delegate from India and world over. This Centre of Excellence will bring together the expertise of industry, academia, regulators, pharma management and marketing expertise, he said.